Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[EQUITIES] Shinhan Investment forecasts Daewoong Pharmaceutical to post earnings decline in Q2
By Korea HeraldPublished : July 15, 2016 - 18:15
[THE INVESTOR] Shinhan Investment expects Daewoong Pharmaceutical’s second quarter operating profit to fall below market estimates, with the figure reaching 9.2 billion won (US$ ) that reflects a 43.7 percent downturn on-year.
Sales are expected to decline 4.2 percent to 194 billion won, mostly due to increased expenses, including those involved with research and development, which are expected to reach 26.3 billion won. The figure reflects a 2 billion won increase, on-year, Shinhan said.
Sales are expected to decline 4.2 percent to 194 billion won, mostly due to increased expenses, including those involved with research and development, which are expected to reach 26.3 billion won. The figure reflects a 2 billion won increase, on-year, Shinhan said.
In the third quarter, the brokerage said Daewoong would post sales of 199 billion won to reflect a 7 percent fall, while sales fall 27.8 percent to 11.1 billion won on-year.
By Kim Ji-hyun (jemmie@heraldcoro.com)
-
Articles by Korea Herald
